Shanghai Junshi Biosciences Co Ltd Asset Resilience Ratio
Shanghai Junshi Biosciences Co Ltd asset resilience ratio. Shanghai Junshi Biosciences Co Ltd (688180) has an Asset Resilience Ratio of 4.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Shanghai Junshi Biosciences Co Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shanghai Junshi Biosciences Co Ltd (2014–2025)
Asset resilience ratio of Shanghai Junshi Biosciences Co Ltd from 2014 to 2025. This chart shows how Shanghai Junshi Biosciences Co Ltd's Asset Resilience Ratio has changed over time. See Shanghai Junshi Biosciences Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Junshi Biosciences Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 688180 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥600.81 Million | 4.85% |
| Total Liquid Assets | CN¥600.81 Million | 4.85% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Junshi Biosciences Co Ltd maintains only 4.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Junshi Biosciences Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Junshi Biosciences Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Shanghai Junshi Biosciences Co Ltd Asset Resilience Ratio by Year (2014–2025)
Shanghai Junshi Biosciences Co Ltd asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Shanghai Junshi Biosciences Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.85% | CN¥600.81 Million ≈ $87.92 Million |
CN¥12.38 Billion ≈ $1.81 Billion |
+0.87pp |
| 2024-12-31 | 3.99% | CN¥430.51 Million ≈ $63.00 Million |
CN¥10.80 Billion ≈ $1.58 Billion |
+3.99pp |
| 2020-12-31 | 0.00% | CN¥17.00K ≈ $2.49K |
CN¥8.01 Billion ≈ $1.17 Billion |
0.00pp |
| 2019-12-31 | 0.00% | CN¥17.00K ≈ $2.49K |
CN¥4.42 Billion ≈ $647.14 Million |
-0.13pp |
| 2018-12-31 | 0.13% | CN¥5.52 Million ≈ $807.16K |
CN¥4.26 Billion ≈ $622.98 Million |
-11.96pp |
| 2017-12-31 | 12.09% | CN¥147.43 Million ≈ $21.57 Million |
CN¥1.22 Billion ≈ $178.48 Million |
-20.42pp |
| 2016-12-31 | 32.50% | CN¥373.47 Million ≈ $54.65 Million |
CN¥1.15 Billion ≈ $168.14 Million |
-38.21pp |
| 2014-12-31 | 70.71% | CN¥235.44 Million ≈ $34.45 Million |
CN¥332.94 Million ≈ $48.72 Million |
-- |
About Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more